Sugi Predict

Sugi Predict / Compounds / SCHEMBL5551897

SCHEMBL5551897

SCHEMBL5551897

CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O

nearest known ligand 0.85

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.85
▸ MEN1 O00255 1/20 0.56
▸ LMNA P02545 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ MAPT P10636 2/20 0.53
▸ KDM4E B2RXH2 1/20 0.52
▸ THRB P10828 1/20 0.52
▸ ALOX15 P16050 1/20 0.52
▸ NFKB1 P19838 1/20 0.52
▸ PTGS2 P35354 1/20 0.52
▸ THPO P40225 1/20 0.52
▸ RECQL P46063 1/20 0.52
▸ BLM P54132 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ FOLH1 Q04609 2/20 0.50
▸ MME P08473 5/20 0.49
▸ LAP3 P28838 2/20 0.47
▸ GNPAT O15228 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5551895 1.00 ALDH1A1 (0.85) ALDH1A1MEN1LMNAKMT2AMAPT
SCHEMBL17948650 1.00 ALDH1A1 (0.85) ALDH1A1MEN1LMNAKMT2AMAPT
Levacetylleucine SCHEMBL714003 0.92 ALDH1A1 (1.00) ALDH1A1MEN1LMNAKMT2AMAPT
Levacetylleucine SCHEMBL282372 0.92 ALDH1A1 (1.00) ALDH1A1MEN1LMNAKMT2AMAPT
Acetylleucine SCHEMBL282371 0.92 ALDH1A1 (1.00) ALDH1A1MEN1LMNAKMT2AMAPT
Levacetylleucine SCHEMBL9438432 0.92 ALDH1A1 (1.00) ALDH1A1MEN1LMNAKMT2AMAPT
Levacetylleucine SCHEMBL18954336 0.90 ALDH1A1 (0.96) ALDH1A1MEN1LMNAKMT2AMAPT
Levacetylleucine SCHEMBL7923132 0.90 ALDH1A1 (0.96) ALDH1A1MEN1LMNAKMT2AMAPT
Levacetylleucine SCHEMBL5527234 0.90 ALDH1A1 (0.96) ALDH1A1MEN1LMNAKMT2AMAPT
Levacetylleucine SCHEMBL5532016 0.90 ALDH1A1 (0.96) ALDH1A1MEN1LMNAKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1131458-A1 VIRAL VECTORS WITH LATE TRANSGENE EXPRESSION CANJI, Inc. (US) 2001-09-12 — — EP claimed
WO-2000029599-A1 VIRAL VECTORS WITH LATE TRANSGENE EXPRESSION CANJI, INC. (US) 2000-05-25 — — WO claimed
WO-2000029573-A2 ADENOVIRAL VECTORS CANJI, INC. (US) 2000-05-25 — — WO claimed
EP-3962559-B1 METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES UNIV HOUSTON SYSTEM (US) 2025-04-16 — — EP disclosed
CN-118662535-B Application of bifidobacterium adolescentis and metabolites thereof in preparation of drugs for improving liver injury 广东药科大学 2025-04-04 — — CN disclosed
CN-119278032-A Enhancement of persistent antitumor immunity by multifactorial immunomodulation 贝勒医学院 2025-01-07 — — CN disclosed
US-20240294581-A1 HETEROLOGOUS PRODUCTION OF LEUPEPTIN IN PROTEASE INHIBITORS AND ANALOGS THEREOF UNIV YALE (US) 2024-09-05 — — US disclosed
CN-110129344-B Improved thymidine kinase gene 吉恩维沃公司 2024-06-18 — — CN disclosed
WO-2024118561-A2 DYSREGULATION OF NEUROPROTEASOMES BY APOE ISOFORMS DRIVES ENDOGENOUS TAU AGGREGATION THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2024-06-06 — — WO disclosed
US-11912742-B2 Heterologous production of leupeptin protease inhibitors and analogs thereof YALE UNIVERSITY (US) 2024-02-27 — — US disclosed
US-11912742-B2 Heterologous production of leupeptin protease inhibitors and analogs thereof YALE UNIVERSITY (US) 2024-02-27 — — US disclosed
US-8703483-B2 Reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds and other chemicals WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2014-04-22 — — US disclosed
WO-2013127981-A1 PROTEASE INHIBITORS FOR TREATING TRICHOMONAS GALLINAE INFECTIONS VETERINÄRMEDIZINISCHE UNIVERSITÄT WIEN (AT) 2013-09-06 — — WO disclosed
US-20070248947-A1 Reagents and Methods for Using Human Embryonic Stem Cells to Evaluate Toxicity of Pharmaceutical Compounds and Other Chemicals WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2007-10-25 — — US disclosed
EP-1131458-A1 VIRAL VECTORS WITH LATE TRANSGENE EXPRESSION CANJI, Inc. (US) 2001-09-12 — — EP disclosed
WO-2000029599-A1 VIRAL VECTORS WITH LATE TRANSGENE EXPRESSION CANJI, INC. (US) 2000-05-25 — — WO disclosed
WO-2000029573-A2 ADENOVIRAL VECTORS CANJI, INC. (US) 2000-05-25 — — WO disclosed
WO-1999064583-A2 COMPOSITIONS AND METHODS FOR MODULATING PROTEOLYTIC DEGRADATION OF INTRACELLULAR TARGETS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALT H AND HUMAN SERVICES (US) 1999-12-16 — — WO disclosed
EP-0783489-A1 ALDEHYDE DERIVATIVES AS UPSTEINE PROTEASE INHIBITORS Takeda Chemical Industries, Ltd. (JP) 1997-07-16 — — EP disclosed
WO-1996010014-A1 ALDEHYDE DERIVATIVES AS UPSTEINE PROTEASE INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1996-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912742-B2 Heterologous production of leupeptin protease inhibitors and analogs thereof LPXN, LAP3, PEPD ALDH1A1 4762/4885MEN1 1920/4885LMNA 615/4885
US-20240294581-A1 HETEROLOGOUS PRODUCTION OF LEUPEPTIN IN PROTEASE INHIBITORS AND ANALOGS THEREOF LPXN, LAP3, PEPD ALDH1A1 4727/4885MEN1 2075/4885LMNA 587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.